Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nersesyan, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nersesyan, A. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 18, No. 3, 307, May 2003
© 2003 UK Environmental Mutagen Society/Oxford University Press

LETTER TO THE EDITOR

Re: Chromosomal aberration, micronucleus and Comet assays on peripheral blood lymphocytes of leprosy patients undergoing multidrug treatment (Mutagenesis, 17, 309–312, 2002)

Armen K. Nersesyan

Laboratory of Carcinogenesis, Cancer Research Centre, 76 Fanardjian Street, Yerevan 52, Armenia

The first 10% of the full text of this article appears below.

I studied with great interest the research findings of Kalaiselvi et al. (2002)Go who evaluated the genetic damage in leprosy patients undergoing multidrug therapy (MDT) by means of the chromosomal aberrations (CA), micronuclei and Comet assays. All assays applied showed genetic damage in treated leprosy patients.

It is known that leprosy patients are different in terms of bacteriological index, immunological status, histology and clinical features (Ridley and Jopling, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?